- Home
- DKL vs ZLAB Comparison
DKL vs ZLAB Comparison
Compare DKL & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DKL | ZLAB |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | DKL | ZLAB |
|---|---|---|
| Price | $48.88 | $17.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $45.50 | ★ $53.52 |
| AVG Volume (30 Days) | 61.5K | ★ 750.8K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 9.16% | N/A |
| EPS Growth | ★ 9.17 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $967,420,000.00 | $441,629,000.00 |
| Revenue This Year | $11.84 | $26.16 |
| Revenue Next Year | $10.55 | $30.62 |
| P/E Ratio | $15.81 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $34.59 | $16.82 |
| 52 Week High | $49.23 | $44.34 |
Technical Indicators
Market Signals| Indicator | DKL | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 67.01 | 40.59 |
| Support Level | $48.01 | $17.47 |
| Resistance Level | $49.02 | $19.14 |
| Average True Range (ATR) | 1.22 | 0.56 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 100.00 | 9.51 |
Price Performance
Historical ComparisonAbout DKL Delek Logistics Partners
Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.